CancerDrs

Breast Cancer clinical trials in New Hampshire

10 actively recruiting breast cancer trials at 4 sites across New Hampshire.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Network

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in New Hampshire:
  • New Hampshire Oncology Hematology PA-Concord — Concord, New Hampshire
  • Solinsky Center for Cancer Care — Manchester, New Hampshire
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achie…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05812807
Sites in New Hampshire:
  • New Hampshire Oncology Hematology PA-Concord — Concord, New Hampshire
  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center — Lebanon, New Hampshire
  • The Dana-Farber Cancer Institute at Londonderry — Londonderry, New Hampshire
  • Solinsky Center for Cancer Care — Manchester, New Hampshire
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metasta…

Sponsor: BriaCell Therapeutics Corporation
NCT ID: NCT06072612
Sites in New Hampshire:
  • Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients

Researchers have learned that about 50% of women do not finish the standard 5-year breast cancer treatment with an aromatase inhibitor. An aromatase inhibitor is hormone therapy that lowers the chance of breast cancer coming back (recurrin…

Sponsor: Dartmouth-Hitchcock Medical Center
NCT ID: NCT07071038
Sites in New Hampshire:
  • Dartmouth Cancer Center — Lebanon, New Hampshire
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in New Hampshire:
  • New Hampshire Oncology Hematology PA-Concord — Concord, New Hampshire
  • Solinsky Center for Cancer Care — Manchester, New Hampshire
View on ClinicalTrials.gov →
Phase 4 Recruiting Industry

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal Growth Factor…

Sponsor: AstraZeneca
NCT ID: NCT07357597
Sites in New Hampshire:
  • Research Site — Lebanon, New Hampshire
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

A Randomized Two-Arm Proof of Concept Study Testing A Novel Approach to Exercise Promotion Based on Affect-regulation

The goal of this clinical trial is to test the effect of an affect-based exercise prescription on moderate-vigorous physical activity participation among survivors of breast cancer who completed primary treatment within the last 5 years. T…

Sponsor: Dartmouth-Hitchcock Medical Center
NCT ID: NCT06258993
Sites in New Hampshire:
  • Dartmouth-Hitchcock Clinic — Lebanon, New Hampshire
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Pilot SMART of a Remotely Delivered, Physical Activity Intervention for Breast Cancer Survivors

The goal of this clinical trial is to evaluate the feasibility of randomizing participants to a "step-up" intervention pathway when they perform \<150 minutes of MVPA at the 6-week data collection burst. Participants who performed \<150 mi…

Sponsor: Dartmouth-Hitchcock Medical Center
NCT ID: NCT07706556
Sites in New Hampshire:
  • Dartmouth-Hitchcock Clinic — Lebanon, New Hampshire
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-11-09